The promise of targeted therapy: Cancer drugs become more specific

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.